The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Analysis.

MLA

O’Donoghue M, et al. “The Efficacy and Safety of Prasugrel with and without a Glycoprotein IIb/IIIa Inhibitor in Patients with Acute Coronary Syndromes Undergoing Percutaneous Intervention: A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Analysis.” Journal of the American College of Cardiology (JACC), vol. 54, no. 8, Aug. 2009, pp. 678–85. EBSCOhost, https://doi.org/10.1016/j.jacc.2009.05.025.

APA

O’Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, & Wiviott SD. (2009). The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Analysis. Journal of the American College of Cardiology (JACC), 54(8), 678–685. https://doi.org/10.1016/j.jacc.2009.05.025

Chicago

O’Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, et al. 2009. “The Efficacy and Safety of Prasugrel with and without a Glycoprotein IIb/IIIa Inhibitor in Patients with Acute Coronary Syndromes Undergoing Percutaneous Intervention: A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Analysis.” Journal of the American College of Cardiology (JACC) 54 (8): 678–85. doi:10.1016/j.jacc.2009.05.025.